Chronic Total Occlusion (CTO) occurs when a coronary artery is completely blocked, usually described as more than 99% stenosed, for a duration that is longer than three months. This results in a significant decrease in blood flow, causing coronary artery disease. If one or more of the coronary arteries are totally blocked, a heart attack may occur. The blocks are caused by build-up of plaque within the artery. The devices used to treat blocked arteries or chronic total occlusion are called chronic total occlusion devices. These devices enable health care providers to remove the block through a minimally invasive procedure. In the event of a coronary artery disease occurrence, chronic total occlusion is frequently identified as the toughest lesion to be remedied by percutaneous coronary intervention. Chronic total occlusion devices help arteries regain their normal function by removing blockages, resulting in improved heart function. They also aid in improving the patient's quality of life by enhancing ventricular function and diminishing symptomatic ischemia.
The global CTO devices market is expected to be driven by a surge in demand for minimally invasive surgical procedures. Improvements in medical finance alternatives, new product launches by major companies, and advanced technologies to improve upon existing devices are expected to favorably influence the CTO devices market in the next few years. Rise in number of patients afflicted with coronary artery disease and peripheral artery disease is expected to increase the use of chronic total occlusion devices globally. The procedures conducted by these devices have a slightly raised risk of damage to kidneys, bleeding at the site of puncture, damage to blood vessels, and marginal tears in the arteries’ inner lining. Certain factors need to be considered while selecting a device. These could include the length of the lesion, ratio of calcification, location of re-entry zones, and availability of a particular device in the facility where the treatment is being carried out. Chronic total occlusion is prevalent in around 30% of patients suffering from cardiovascular disease who undergo angiography.
The global CTO devices market can be segmented based on equipment, end-user, and region. In terms of equipment, the global CTO devices market can be classified into micro catheters, guide wires, crossing devices, re-entry devices, and others. The guide wires segment is expected to constitute a dominant share of the CTO devices market during the forecast period in terms of type. Based on end-user, the global CTO devices market can be segmented into hospitals, diagnostic centers, ambulatory care centers, and others. Advancement in crossing technologies has enabled health care providers in hospitals to intercept lesions or blockages with higher success ratios.
In terms of region, the global CTO devices market can be divided into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is anticipated to be a dominant region of the CTO devices market during the forecast period owing to innovations and improvement in techniques. Rise in investments in health care infrastructure in Asia Pacific is expected to positively influence the CTO devices market in the near future. In Europe, trials were successfully conducted to compare chronic total occlusion devices performance with optimized medical therapy. The trials showed an optimistic success rate and minimal procedural risk, which is estimated to increase the preference for chronic total occlusion devices in the next few years.
The key players operating in the global CTO devices market are Boston Scientific Corporation, Terumo Europe NV, Medtronic, Cardinal Health (Cordis), Spectranetics, BARD Peripheral Vascular, Baylis Medical, and Soundbite Medical Solutions.